<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066611</url>
  </required_header>
  <id_info>
    <org_study_id>263-02</org_study_id>
    <nct_id>NCT01066611</nct_id>
  </id_info>
  <brief_title>Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Investigate the Safety of CAL-263 in Allergic Rhinitis Subjects and Effects on the Response to Environmental Chamber Allergen Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effect of CAL-263 in subjects with
      allergic rhinitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, randomized, double-blind crossover study of CAL-263, an oral inhibitor of PI3K
      delta, in patients with allergic rhinitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety of CAL-263 in allergic rhinitis subjects</measure>
    <time_frame>46 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the efficacy of CAL-263 on total nasal symptom scores following an allergen challenge in allergic rhinitis subjects</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CAL-263</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAL-263</intervention_name>
    <description>CAL-263 10 mg or placebo once daily for 7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>CAL-263 10 mg or placebo once daily for 7 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 and &lt;55 years

          2. Has a history of seasonal allergic rhinitis for at least 2 years

          3. Has sensitivity to grass pollen demonstrated by a positive response to skin prick
             testing

          4. Has a positive Radio Allergen Sorbent Test (class 2 or greater) for grass pollen
             during the previous 12 months or at screening

          5. Is otherwise healthy

          6. Is able to provide written informed consent

        Exclusion Criteria:

          1. Is a female of childbearing

          2. History of chronic nasal or upper respiratory tract symptoms or disorders other than
             allergic rhinitis

          3. History of nonallergic rhinitis, chronic sinusitis or severe asthma

          4. Has a nasal condition likely to affect the outcome of the study

          5. Is currently taking regular medication, whether prescribed or not, including
             corticosteroids, vitamins, macrolides, anti-fungal agents and herbal remedies

          6. Has taken a prohibited medication within the specified interval prior to Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedrich Horak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vienna Challenge Chamber</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vienna Challenge Chamber</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Langdon Miller, M.D., VP Clinical Research, Oncology</name_title>
    <organization>Gilead Sciences</organization>
  </responsible_party>
  <keyword>Allergic Rhinitis</keyword>
  <keyword>Allergy</keyword>
  <keyword>Phosphatidylinositol 3-kinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

